HENNIGSDORF, Germany–(BUSINESS WIRE)–For healthcare professionals facing the complexity of daily requirements in emergency situations, a new point-of-care test, Samsung IB B·R·A·H·M·S PCT assay, offers an integrated solution for accurate sepsis diagnosis and antibiotic stewardship. The test, which recently received a CE mark for use in Europe, may further improve medical decision-making about risk assessment and therapy management. B·R·A·H·M·S PCT (procalcitonin) assays are known to clinicians for high-quality and reliable early detection of bacterial infections based on standardized cutoffs.

“With the addition of this new test, we will significantly improve our ability to make PCT testing available to a broader patient population in Europe, particularly for point-of-care diagnostics,” said Marc Tremblay, president of Thermo Fisher’s clinical diagnostics business. “Early diagnosis is key in preventing sepsis, a global problem resulting in greater mortality rates than prostate cancer, breast cancer and AIDS combined1. Early identification and treatment of sepsis reduces the cost of providing healthcare. Delayed sepsis treatment may involve an extended stay in the intensive care unit or complex antibiotic therapies.”

As the first co-developed product by Thermo Fisher and Samsung Electronics, the Samsung IB B·R·A·H·M·S PCT test enables fast and easy Procalcitonin determination in acute care settings as testing results in 20 minutes while providing outstanding portability and connectivity. The quantitative point of care test aids early detection and diagnosis of clinically relevant bacterial infections to assess the degree of severity and to prognosticate the outcome of systemic bacterial infection, sepsis, severe sepsis, and septic shock.

The Samsung IB B·R·A·H·M·S PCT test is not available for sale in some countries, including the United States.

The unique alliance between Samsung Electronics and Thermo Fisher will continue to bring further innovations in the point-of-care testing market to fulfill customer needs and improve patient outcomes.

More information about the Samsung IB B·R·A·H·M·S PCT test can be found here or by visiting www.thermoscientific.com/procalcitonin.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

About Samsung Electronics Co., Ltd.
Samsung Electronics Co., Ltd. inspires the world and shapes the future with transformative ideas and technologies that redefine the worlds of TVs, smartphones, wearable devices, tablets, cameras, digital appliances, printers, medical equipment, network systems, and semiconductor and LED solutions. We are also leading in the Internet of Things space with the open platform SmartThings, our broad range of smart devices, and through proactive cross-industry collaboration. We employ 319,000 people across 84 countries with annual sales of US $196 billion. To discover more, and for the latest news, feature articles and press material, please visit the Samsung Newsroom at news.samsung.com.

Reference
1www.world-sepsis-day.org

Source
http://news.thermofisher.com/press-release/thermo-fisher-scientific-launches-new-b%C2%B7r%C2%B7a%C2%B7h%C2%B7m%C2%B7s-pct-testing-solution-europe-samsung-